Ami M. Kabadi , Maria Katherine Mejia-Guerra , John D. Graef , Sohrab Z. Khan , Eric M. Walton , Xinzhu Wang , Charles A. Gersbach , Rachael Potter
{"title":"基于 AAV 的 CRISPR-Cas9 基因组编辑：挑战与工程机遇","authors":"Ami M. Kabadi , Maria Katherine Mejia-Guerra , John D. Graef , Sohrab Z. Khan , Eric M. Walton , Xinzhu Wang , Charles A. Gersbach , Rachael Potter","doi":"10.1016/j.cobme.2023.100517","DOIUrl":null,"url":null,"abstract":"<div><p>Recent innovations in the field of gene therapy have paved the way for advances towards developing genome editing medicines. Despite these steps forward, challenges with viral delivery of genome editing tools persist. Efforts currently underway include developing next-generation genome editors, overcoming adeno-associated virus (AAV) packaging restrictions, improving AAV genome integrity, engineering novel AAV capsids, and minimizing the immune response. This review discusses current challenges in delivering CRISPR-Cas nuclease-based genome editing therapies using AAV and highlights emerging methods to overcome these obstacles. This includes developing smaller payloads and regulatory elements, advancing novel sequencing methods for vector characterization, engineering capsids with enhanced potency, tissue-selectivity, and ability to evade pre-existing antibodies, controlling transgene expression, and minimizing the immune response to Cas proteins.</p></div>","PeriodicalId":36748,"journal":{"name":"Current Opinion in Biomedical Engineering","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468451123000739/pdfft?md5=23fd7e302b12d0dee1de084f88f1a6ed&pid=1-s2.0-S2468451123000739-main.pdf","citationCount":"0","resultStr":"{\"title\":\"AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities\",\"authors\":\"Ami M. Kabadi , Maria Katherine Mejia-Guerra , John D. Graef , Sohrab Z. Khan , Eric M. Walton , Xinzhu Wang , Charles A. Gersbach , Rachael Potter\",\"doi\":\"10.1016/j.cobme.2023.100517\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Recent innovations in the field of gene therapy have paved the way for advances towards developing genome editing medicines. Despite these steps forward, challenges with viral delivery of genome editing tools persist. Efforts currently underway include developing next-generation genome editors, overcoming adeno-associated virus (AAV) packaging restrictions, improving AAV genome integrity, engineering novel AAV capsids, and minimizing the immune response. This review discusses current challenges in delivering CRISPR-Cas nuclease-based genome editing therapies using AAV and highlights emerging methods to overcome these obstacles. This includes developing smaller payloads and regulatory elements, advancing novel sequencing methods for vector characterization, engineering capsids with enhanced potency, tissue-selectivity, and ability to evade pre-existing antibodies, controlling transgene expression, and minimizing the immune response to Cas proteins.</p></div>\",\"PeriodicalId\":36748,\"journal\":{\"name\":\"Current Opinion in Biomedical Engineering\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2023-12-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2468451123000739/pdfft?md5=23fd7e302b12d0dee1de084f88f1a6ed&pid=1-s2.0-S2468451123000739-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Biomedical Engineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468451123000739\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Biomedical Engineering","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468451123000739","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities
Recent innovations in the field of gene therapy have paved the way for advances towards developing genome editing medicines. Despite these steps forward, challenges with viral delivery of genome editing tools persist. Efforts currently underway include developing next-generation genome editors, overcoming adeno-associated virus (AAV) packaging restrictions, improving AAV genome integrity, engineering novel AAV capsids, and minimizing the immune response. This review discusses current challenges in delivering CRISPR-Cas nuclease-based genome editing therapies using AAV and highlights emerging methods to overcome these obstacles. This includes developing smaller payloads and regulatory elements, advancing novel sequencing methods for vector characterization, engineering capsids with enhanced potency, tissue-selectivity, and ability to evade pre-existing antibodies, controlling transgene expression, and minimizing the immune response to Cas proteins.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
